<?xml version="1.0" ?>
<!DOCTYPE PubmedArticleSet PUBLIC "-//NLM//DTD PubMedArticle, 1st January 2024//EN" "https://dtd.nlm.nih.gov/ncbi/pubmed/out/pubmed_240101.dtd">
<PubmedArticleSet>
<PubmedArticle><MedlineCitation Status="PubMed-not-MEDLINE" Owner="NLM"><PMID Version="1">34696288</PMID><DateRevised><Year>2024</Year><Month>04</Month><Day>03</Day></DateRevised><Article PubModel="Electronic"><Journal><ISSN IssnType="Print">2076-393X</ISSN><JournalIssue CitedMedium="Print"><Volume>9</Volume><Issue>10</Issue><PubDate><Year>2021</Year><Month>Oct</Month><Day>15</Day></PubDate></JournalIssue><Title>Vaccines</Title><ISOAbbreviation>Vaccines (Basel)</ISOAbbreviation></Journal><ArticleTitle>Vaccinating Adolescents and Children Significantly Reduces COVID-19 Morbidity and Mortality across All Ages: A Population-Based Modeling Study Using the UK as an Example.</ArticleTitle><ELocationID EIdType="pii" ValidYN="Y">1180</ELocationID><ELocationID EIdType="doi" ValidYN="Y">10.3390/vaccines9101180</ELocationID><Abstract><AbstractText>Debate persists around the risk-benefit balance of vaccinating adolescents and children against COVID-19. Central to this debate is quantifying the contribution of adolescents and children to the transmission of SARS-CoV-2, and the potential impact of vaccinating these age groups. In this study, we present a novel SEIR mathematical disease transmission model that quantifies the impact of different vaccination strategies on population-level SARS-CoV-2 infections and clinical outcomes. The model employs both age- and time-dependent social mixing patterns to capture the impact of changes in restrictions. The model was used to assess the impact of vaccinating adolescents and children on the natural history of the COVID-19 pandemic across all age groups, using the UK as an example. The base case model demonstrates significant increases in COVID-19 disease burden in the UK following a relaxation of restrictions, if vaccines are limited to those &#x2265;18 years and vulnerable adolescents (&#x2265;12 years). Including adolescents and children in the vaccination program could reduce overall COVID-related mortality by 57%, and reduce cases of long COVID by 75%. This study demonstrates that vaccinating adolescents and children has the potential to play a vital role in reducing SARS-CoV-2 infections, and subsequent COVID-19 morbidity and mortality, across all ages. Our results have major global public health implications and provide valuable information to inform a potential pandemic exit strategy.</AbstractText></Abstract><AuthorList CompleteYN="Y"><Author ValidYN="Y"><LastName>Shiri</LastName><ForeName>Tinevimbo</ForeName><Initials>T</Initials><AffiliationInfo><Affiliation>Health Economics and Outcomes Research Ltd., Cardiff CF23 8RB, UK.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Evans</LastName><ForeName>Marc</ForeName><Initials>M</Initials><AffiliationInfo><Affiliation>Diabetes Resource Centre, University Hospital Llandough, Cardiff CF64 2XX, UK.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Talarico</LastName><ForeName>Carla A</ForeName><Initials>CA</Initials><AffiliationInfo><Affiliation>Moderna Inc., Cambridge, MA 02139, USA.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Morgan</LastName><ForeName>Angharad R</ForeName><Initials>AR</Initials><AffiliationInfo><Affiliation>Health Economics and Outcomes Research Ltd., Cardiff CF23 8RB, UK.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Mussad</LastName><ForeName>Maaz</ForeName><Initials>M</Initials><AffiliationInfo><Affiliation>Ashfield Healthcare on Behalf of Moderna, Ashby-de-la-Zouch LE65 1HW, UK.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Buck</LastName><ForeName>Philip O</ForeName><Initials>PO</Initials><AffiliationInfo><Affiliation>Moderna Inc., Cambridge, MA 02139, USA.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>McEwan</LastName><ForeName>Phil</ForeName><Initials>P</Initials><AffiliationInfo><Affiliation>Health Economics and Outcomes Research Ltd., Cardiff CF23 8RB, UK.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Strain</LastName><ForeName>William David</ForeName><Initials>WD</Initials><Identifier Source="ORCID">0000-0002-6826-418X</Identifier><AffiliationInfo><Affiliation>Diabetes and Vascular Research Centre, University of Exeter Medical School, Exeter EX1 2HZ, UK.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>The Academic Department of Healthcare for Older Adults, Royal Devon and Exeter Hospital, Exeter EX2 5DW, UK.</Affiliation></AffiliationInfo></Author></AuthorList><Language>eng</Language><GrantList CompleteYN="Y"><Grant><GrantID>N/a</GrantID><Agency>Moderna Therapeutics (United States)</Agency><Country/></Grant></GrantList><PublicationTypeList><PublicationType UI="D016428">Journal Article</PublicationType></PublicationTypeList><ArticleDate DateType="Electronic"><Year>2021</Year><Month>10</Month><Day>15</Day></ArticleDate></Article><MedlineJournalInfo><Country>Switzerland</Country><MedlineTA>Vaccines (Basel)</MedlineTA><NlmUniqueID>101629355</NlmUniqueID><ISSNLinking>2076-393X</ISSNLinking></MedlineJournalInfo><KeywordList Owner="NOTNLM"><Keyword MajorTopicYN="N">COVID-19</Keyword><Keyword MajorTopicYN="N">SARS-CoV-2</Keyword><Keyword MajorTopicYN="N">adolescent</Keyword><Keyword MajorTopicYN="N">coronavirus</Keyword><Keyword MajorTopicYN="N">disease transmission model</Keyword><Keyword MajorTopicYN="N">vaccination</Keyword></KeywordList><CoiStatement>T.S., A.R.M. and P.M. are employees of Health Economics and Outcomes Research Ltd., Cardiff, UK. Health Economics and Outcomes Research Ltd. received fees from Moderna in relation to this study. M.M. is an employee of Moderna, Inc. C.A.T. and P.O.B. are employees of Moderna, Inc. and hold Moderna stocks/stock options.</CoiStatement></MedlineCitation><PubmedData><History><PubMedPubDate PubStatus="received"><Year>2021</Year><Month>9</Month><Day>11</Day></PubMedPubDate><PubMedPubDate PubStatus="revised"><Year>2021</Year><Month>9</Month><Day>29</Day></PubMedPubDate><PubMedPubDate PubStatus="accepted"><Year>2021</Year><Month>10</Month><Day>4</Day></PubMedPubDate><PubMedPubDate PubStatus="entrez"><Year>2021</Year><Month>10</Month><Day>26</Day><Hour>1</Hour><Minute>2</Minute></PubMedPubDate><PubMedPubDate PubStatus="pubmed"><Year>2021</Year><Month>10</Month><Day>27</Day><Hour>6</Hour><Minute>0</Minute></PubMedPubDate><PubMedPubDate PubStatus="medline"><Year>2021</Year><Month>10</Month><Day>27</Day><Hour>6</Hour><Minute>1</Minute></PubMedPubDate><PubMedPubDate PubStatus="pmc-release"><Year>2021</Year><Month>10</Month><Day>15</Day></PubMedPubDate></History><PublicationStatus>epublish</PublicationStatus><ArticleIdList><ArticleId IdType="pubmed">34696288</ArticleId><ArticleId IdType="pmc">PMC8537561</ArticleId><ArticleId IdType="doi">10.3390/vaccines9101180</ArticleId><ArticleId IdType="pii">vaccines9101180</ArticleId></ArticleIdList><ReferenceList><Reference><Citation>World Health Organisation  WHO Coronavirus Disease (COVID-19) Dashboard.  [(accessed on 26 July 2021)].  Available online:  https://covid19.who.int/</Citation></Reference><Reference><Citation>World Health Organization  Policy Brief 39. In the Wake of the Pandemic: Preparing for Long COVID. 2021.  [(accessed on 26 July 2021)].  Available online:  https://apps.who.int/iris/bitstream/handle/10665/339629/Policy-brief-39-1997-8073-eng.pdf.</Citation></Reference><Reference><Citation>GOV.UK  Press Release: JCVI Issues Advice on COVID-19 Vaccination of Children and Young People.  [(accessed on 26 July 2021)];2021  Available online:  https://www.gov.uk/government/news/jcvi-issues-advice-on-covid-19-vaccination-of-children-and-young-people.</Citation></Reference><Reference><Citation>Frenck R.W., Jr., Klein N.P., Kitchin N., Gurtman A., Absalon J., Lockhart S., Perez J.L., Walter E.B., Senders S., Bailey R., et al. Safety, Immunogenicity, and Efficacy of the BNT162b2 COVID-19 Vaccine in Adolescents. N. Engl. J. Med. 2021;385:239&#x2013;250. doi: 10.1056/NEJMoa2107456.</Citation><ArticleIdList><ArticleId IdType="doi">10.1056/NEJMoa2107456</ArticleId><ArticleId IdType="pmc">PMC8174030</ArticleId><ArticleId IdType="pubmed">34043894</ArticleId></ArticleIdList></Reference><Reference><Citation>Ali K., Berman G., Zhou H., Deng W., Faughnan V., Coronado-Voges M., Ding B., Dooley J., Girard B., Hillebrand W., et al. Evaluation of mRNA-1273 SARS-CoV-2 Vaccine in Adolescents. N. Engl. J. Med. 2021 doi: 10.1056/NEJMoa2109522.</Citation><ArticleIdList><ArticleId IdType="doi">10.1056/NEJMoa2109522</ArticleId><ArticleId IdType="pmc">PMC8385554</ArticleId><ArticleId IdType="pubmed">34379915</ArticleId></ArticleIdList></Reference><Reference><Citation>U.S. Food and Drug Administration  Coronavirus (COVID-19) Update: FDA Authorizes Pfizer-BioNTech COVID-19 Vaccine for Emergency Use in Adolescents in Another Important Action in Fight Against Pandemic 2021.  [(accessed on 26 July 2021)]; Available online:  https://www.fda.gov/news-events/press-announcements/coronavirus-covid-19-update-fda-authorizes-pfizer-biontech-covid-19-vaccine-emergency-use.</Citation></Reference><Reference><Citation>European Medicines Agency  First COVID-19 Vaccine Approved for Children Aged 12 to 15 in EU2021.  [(accessed on 26 July 2021)].  Available online:  https://www.ema.europa.eu/en/news/first-covid-19-vaccine-approved-children-aged-12-15-eu.</Citation></Reference><Reference><Citation>Medicines and Healthcare Products Regulatory Agency  The MHRA Concludes Positive Safety Profile for Pfizer/BioNTech Vaccine in 12- to 15-Year-Olds.  [(accessed on 26 July 2021)];2021  Available online:  https://www.gov.uk/government/news/the-mhra-concludes-positive-safety-profile-for-pfizerbiontech-vaccine-in-12-to-15-year-olds.</Citation></Reference><Reference><Citation>Moderna  EMA Committee for Medicinal Products for Human Use (CHMP) Adopts Positive Opinion Recommending Authorization for the Use of the Moderna COVID-19 Vaccine in Adolescents (12&#x2013;17 Years of Age) in the European Union. 2021.  [(accessed on 26 July 2021)].  Available online:  https://investors.modernatx.com/news-releases/news-release-details/ema-committee-medicinal-products-human-use-chmp-adopts-positive.</Citation></Reference><Reference><Citation>Daley D.J., Gani J. Epidemic Modelling: An Introduction. Cambridge University Press; Cambridge, UK: 2001.</Citation></Reference><Reference><Citation>Dietz K., Heesterbeek J.A. Daniel Bernoulli&#x2019;s epidemiological model revisited. Math. Biosci. 2002;180:1&#x2013;21. doi: 10.1016/S0025-5564(02)00122-0.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/S0025-5564(02)00122-0</ArticleId><ArticleId IdType="pubmed">12387913</ArticleId></ArticleIdList></Reference><Reference><Citation>Kermack W.O., McKendrick A.G. Contributions to the mathematical theory of epidemics&#x2014;II. The problem of endemicity. Bull. Math. Biol. 1991;53:57&#x2013;87. doi: 10.1007/bf02464424.</Citation><ArticleIdList><ArticleId IdType="doi">10.1007/bf02464424</ArticleId><ArticleId IdType="pubmed">2059742</ArticleId></ArticleIdList></Reference><Reference><Citation>Gurdasani D., Drury J., Greenhalgh T., Griffin S., Haque Z., Hyde Z., Katzourakis A., McKee M., Michie S., Pagel C., et al. Mass infection is not an option: We must do more to protect our young. Lancet. 2021;398:297&#x2013;298. doi: 10.1016/S0140-6736(21)01589-0.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/S0140-6736(21)01589-0</ArticleId><ArticleId IdType="pmc">PMC8262842</ArticleId><ArticleId IdType="pubmed">34245669</ArticleId></ArticleIdList></Reference><Reference><Citation>GOV.UK  Week 27 2021: Attendance in Education and Early Years Settings During the Coronavirus (COVID-19) Outbreak.  [(accessed on 26 July 2021)];2021  Available online:  https://explore-education-statistics.service.gov.uk/find-statistics/attendance-in-education-and-early-years-settings-during-the-coronavirus-covid-19-outbreak/2021-week-27.</Citation></Reference><Reference><Citation>Milne G., Carrivick J., Whyatt D. Reliance on Vaccine-Only Pandemic Mitigation Strategies Is Compromised by Highly Transmissible COVID-19 Variants: A Mathematical Modelling Study. 2021.  [(accessed on 28 September 2021)].  Available online:  https://papers.ssrn.com/sol3/papers.cfm?abstract_id=3911100#.</Citation></Reference><Reference><Citation>Milman O., Yelin I., Aharony N., Katz R., Herzel E., Ben-Tov A., Kuint J., Gazit S., Chodick G., Patalon T., et al. Community-level evidence for SARS-CoV-2 vaccine protection of unvaccinated individuals. Nat. Med. 2021;27:1367&#x2013;1369. doi: 10.1038/s41591-021-01407-5.</Citation><ArticleIdList><ArticleId IdType="doi">10.1038/s41591-021-01407-5</ArticleId><ArticleId IdType="pubmed">34113015</ArticleId></ArticleIdList></Reference><Reference><Citation>Havers F.P., Whitaker M., Self J.L., Chai S.J., Kirley P.D., Alden N.B., Kawasaki B., Meek J., Yousey-Hindes K., Anderson E.J., et al. Hospitalization of Adolescents Aged 12-17 Years with Laboratory-Confirmed COVID-19&#x2014;COVID-NET, 14 States, March 1, 2020&#x2013;April 24, 2021. Morb. Mortal. Wkly. Rep. 2021;70:851&#x2013;857. doi: 10.15585/mmwr.mm7023e1.</Citation><ArticleIdList><ArticleId IdType="doi">10.15585/mmwr.mm7023e1</ArticleId><ArticleId IdType="pmc">PMC8191866</ArticleId><ArticleId IdType="pubmed">34111061</ArticleId></ArticleIdList></Reference><Reference><Citation>Odd D., Stoianova S., Williams T., Sleap V., Blair P., Fleming P., Wolfe I., Luyt K. Child mortality in England during the COVID-19 pandemic. Arch. Dis. Child. 2021 doi: 10.1136/archdischild-2020-320899.</Citation><ArticleIdList><ArticleId IdType="doi">10.1136/archdischild-2020-320899</ArticleId><ArticleId IdType="pmc">PMC8219479</ArticleId><ArticleId IdType="pubmed">34911683</ArticleId></ArticleIdList></Reference><Reference><Citation>G&#xf6;tzinger F., Santiago-Garc&#xed;a B., Noguera-Juli&#xe1;n A., Lanaspa M., Lancella L., Carducci F., COVID-19 Study Group COVID-19 in children and adolescents in Europe: A multinational, multicentre cohort study. Lancet Child. Adolesc. Health. 2020;4:653&#x2013;661. doi: 10.1016/S2352-4642(20)30177-2.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/S2352-4642(20)30177-2</ArticleId><ArticleId IdType="pmc">PMC7316447</ArticleId><ArticleId IdType="pubmed">32593339</ArticleId></ArticleIdList></Reference><Reference><Citation>Mahase E. COVID-19: Concerns grow over inflammatory syndrome emerging in children. BMJ. 2020;369:m1710. doi: 10.1136/bmj.m1710.</Citation><ArticleIdList><ArticleId IdType="doi">10.1136/bmj.m1710</ArticleId><ArticleId IdType="pubmed">32345602</ArticleId></ArticleIdList></Reference><Reference><Citation>Feldstein L.R., Rose E.B., Horwitz S.M., Collins J.P., Newhams M.M., Son M.B.F., Newburger J.W., Kleinman L.C., Heidemann S.M., Martin A.A., et al. Multisystem Inflammatory Syndrome in U.S. Children and Adolescents. N. Engl. J. Med. 2020;383:334&#x2013;346. doi: 10.1056/NEJMoa2021680.</Citation><ArticleIdList><ArticleId IdType="doi">10.1056/NEJMoa2021680</ArticleId><ArticleId IdType="pmc">PMC7346765</ArticleId><ArticleId IdType="pubmed">32598831</ArticleId></ArticleIdList></Reference><Reference><Citation>Kaushik A., Gupta S., Sood M., Sharma S., Verma S. A Systematic Review of Multisystem Inflammatory Syndrome in Children Associated With SARS-CoV-2 Infection. Pediatr. Infect. Dis. J. 2020;39:e340&#x2013;e346. doi: 10.1097/INF.0000000000002888.</Citation><ArticleIdList><ArticleId IdType="doi">10.1097/INF.0000000000002888</ArticleId><ArticleId IdType="pubmed">32925547</ArticleId></ArticleIdList></Reference><Reference><Citation>Buonsenso D., Munblit D., de Rose C., Sinatti D., Ricchiuto A., Carfi A., Valentini P. Preliminary evidence on long COVID in children. Acta Paediatr. 2021;110:2208&#x2013;2211. doi: 10.1111/apa.15870.</Citation><ArticleIdList><ArticleId IdType="doi">10.1111/apa.15870</ArticleId><ArticleId IdType="pmc">PMC8251440</ArticleId><ArticleId IdType="pubmed">33835507</ArticleId></ArticleIdList></Reference><Reference><Citation>Ludvigsson J.F. Case report and systematic review suggest that children may experience similar long-term effects to adults after clinical COVID-19. Acta Paediatr. 2021;110:914&#x2013;921. doi: 10.1111/apa.15673.</Citation><ArticleIdList><ArticleId IdType="doi">10.1111/apa.15673</ArticleId><ArticleId IdType="pmc">PMC7753397</ArticleId><ArticleId IdType="pubmed">33205450</ArticleId></ArticleIdList></Reference><Reference><Citation>Brackel C.L.H., Lap C.R., Buddingh E.P., Houten M.A., van der Sande L.J.T.M., Langereis E.J., Bannier M.A.G.E., Pijnenburg M.W.H., Hashimoto S., Terheggen-Lagro S.W.J. Pediatric long-COVID: An overlooked phenomenon? Pediatr. Pulmonol. 2021;56:2495&#x2013;2502. doi: 10.1002/ppul.25521.</Citation><ArticleIdList><ArticleId IdType="doi">10.1002/ppul.25521</ArticleId><ArticleId IdType="pmc">PMC8242715</ArticleId><ArticleId IdType="pubmed">34102037</ArticleId></ArticleIdList></Reference><Reference><Citation>Office for National Statistics  Prevalence of Ongoing Symptoms Following Coronavirus (COVID-19) Infection in the UK: 1 July 2021.  [(accessed on 26 July 2021)]; Available online:  https://www.ons.gov.uk/peoplepopulationandcommunity/healthandsocialcare/conditionsanddiseases/bulletins/prevalenceofongoingsymptomsfollowingcoronaviruscovid19infectionintheuk/1july2021.</Citation></Reference><Reference><Citation>Ashikkali L., Carroll W., Johnson C. The indirect impact of COVID-19 on child health. Paediatr. Child Health. 2020;30:430&#x2013;437. doi: 10.1016/j.paed.2020.09.004.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.paed.2020.09.004</ArticleId><ArticleId IdType="pmc">PMC7494255</ArticleId><ArticleId IdType="pubmed">32959000</ArticleId></ArticleIdList></Reference><Reference><Citation>Wise J. COVID-19: Should we be worried about reports of myocarditis and pericarditis after mRNA vaccines? BMJ. 2021;373:n1635. doi: 10.1136/bmj.n1635.</Citation><ArticleIdList><ArticleId IdType="doi">10.1136/bmj.n1635</ArticleId><ArticleId IdType="pubmed">34167952</ArticleId></ArticleIdList></Reference><Reference><Citation>ClinicalTrials.Gov  A Study to Evaluate Safety and Effectiveness of mRNA-1273 COVID-19 Vaccine in Healthy Children between 6 Months of Age and Less than 12 Years of Age.  [(accessed on 26 July 2021)];2021  Available online:  https://clinicaltrials.gov/ct2/show/NCT04796896.</Citation></Reference><Reference><Citation>ClinicalTrials.Gov  Study to Evaluate the Safety, Tolerability, and Immunogenicity of an RNA Vaccine Candidate against COVID-19 in Healthy Children &lt;12 Years of Age.  [(accessed on 26 July 2021)];2021  Available online:  https://clinicaltrials.gov/ct2/show/NCT04816643.</Citation></Reference></ReferenceList></PubmedData></PubmedArticle></PubmedArticleSet>